Abstract
The clinical and immunohaeamatological effects of recombinant humen interleukin-2 (rhIL-2) administration were evaluated in normal dogs. Three groups of three dogs per group were administered rhIL-2 subcutaneously at a dose of 6 × 104 IU, 6 × 105 IU, or 6 × 106 IU/kg once daily for five consecutive days. Toxic clinical signs were limited primarily to diarrhoea, the severity of which, was dose dependent, with resolution within 7 days of the last rhIL-2 injection. Marked circulating eosinophilia occurred in dogs of the two highest dose groups and transient rise in blood lymphocyte numbers occurred in dogs given the highest dose of rhIL-2. The most significant immunological effects were elevated in vitro conA and pokeweed mitogen-stimulated lymphocyte blastogenic responsiveness in the highest dose group and dose-dependent elevation of antigen-specific antibody (IgG and IgM) production. Peak relative antibody production was markedly elevated, as compared to controls, in dogs administered 6 × 105 IU, 6 × 106 IU rhIL-2/kg.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Da Pozzo LF, Hough KL, Holder WD Jr (1992) Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs. Surgery 111:326–334
Ettinghausen SE, Rosenberg SA (1986) Immunotherapy of murine sarcomas using lymphokine-activated killer (LAK) cells: optimization of the schedule and route of administration of recombinant interleukin 2. Cancer Res 46:2784–2792
Farrar WL, Jognson HM, Rarrar JJ (1981) Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin 2. J Immunol 126:1120–1125
Fenwick BW, Schore CE, Osburn BI (1988) Human recombinant interleukin-2125 induced in vitro proliferation of equine, caprine, ovine, and canine and feline peripheral blood lymphocytes. Comp Immunol Microbiol Infect Dis 11:51–60
Flomenberg N, Welte K, Mertelsman R et al. (1983) Interleukin 2 dependent natural killer (NK) cell lines from patients with primary T cell immunodeficiencies. J Immunol 130:2635–2643
Gallatin M, St John TP, Siegleman M et al. (1986) Lymphocyte homing receptors. Cell 44:673–680
Gilles S, Smith KA (1977) Long-term culture of tumour-specific cytotoxic T cells. Nature 268:154–156
Grimm EA, Mazumber A, Zhang HZ et al. (1982) Lympholine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interluekin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823–1841
Herberman RB (1987) Adoptive therapy for cancer with interleukin-2-activated killer cells. Cancer Bull 39:6–12
Jardine JH, Jackson HJ, Lotzova E et al. (1989) Tumoricidial effect of interleukin-2-activated killer cells in canines. Vet Immunol Immunopathol 21:153–160
Kauttab NM, Maizel AL (1987) Interleukin 2. Its role in the regulation of T-cell proliferation. Cancer Bull 39:51–60
Kedar E, Chriqui-Zeira E, Kyriazis (1984) Immunotherapy of mice and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes. J Biol Response Med 3:517–526
Lotze MT, Matory YL, Rayner AA et al. (1986) Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58:2764–2772
Lum LG (1987) The kinetics of immune reconstitution after human marrow transplantation. Blood 69:369–380
Lum LG, Munn NA, Schanfield MS et al. (1986) The detection of specific antibody formation to recall antigens after human bone marrow transplantation. Blood 67:582–587
Mier JW (1987) Therapeutic uses of recombinant interleukin-2 in patients with cancer. Cancer Bull 39:19–24
Morgan DA, Ruscetti FW, Gallo RC (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193:1007–1008
Mitchel DH, Winthrow SJ, Johnston MR et al. (1991) Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors. Am J Vet Res 52:1132–1136
Ralph P, Jeong G, Welte K et al. (1984) Stimulation of immunoglobulin secretion in human B lymphocytes as a direct effect of high concentrations of IL 2. J Immunol 133:2442–2445
Raskin RE, Holcomb CS, Maxwell AK (1991) Effects of human recombinant interleukin 2 on in vitro tumor cytotoxicity in dogs. Am J Vet Res 52:2029–2032
Rosenberg S (1984) Adoptive immunotherapy of cancer: accomplishments and prospects. Cancer Treat Rep 68:233–255
Rosenberg SA, Mule J, Shu S et al. (1985a) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high dose recombinant interleukin-2. J Exp Med 161:1169–1188
Rosenberg SA, Lotze MT, Muul LM et al. (1985b) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin 2. N Engl J Med 313:1485–1492
Rosenberg M, Ettinghausen SE, Rosenberg SA (1986) Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 137:1735–1742
Scala G, Djeu JY, Allavena P et al. (1986) Cytokine secretion and non-cytotoxic functions of human large granular lymphocytes. In: Lotzova E (ed) Immunobiology of natural killer cells. CRC Press, Boca Raton, FL, pp 133–144
Shifrine M, Taylor NJ, Rosenblatt LS et al. (1978) Comparison of whole blood and purified canine lymphocytes in a lymphocytestimulation microassay. Am J Vet Res 39:687–690
Storb R, Thomas E (1985) Graft-versus-host disease in dog and man: the Seattle experience. Immunol Rev 88:215–238
Stott JL, Fenwick BW, Osburn BI (1986) Human recombinant interleukin-2 augments in vitro blastogenesis of bovine and porcine lymphocytes. Vet Immunol Immunopathol 13:31–38
Subramanian N, Bray M (1987) Interleukin-1 releases histamine from human basophils and mast cells in vitro. J Immunol 138:271–275
Tompkins MB, Novotney C, Grindem CB et al. (1990) Human recombinant interleukin-2 induces maturation and activation signals for feline eosinophils in vivo. J Leukoc Biol 48:531–540
Voller A, Bidwell DE, Bartlett A (1979) The enzyme linked immunosorbent assay (ELIZA). A guide with abstracts of microplate applications. Dynatech Laboratories Inc. Alexandria, VA, pp 7–41
Vriesendorp HM, van Bekkum W (1980) Bone marrow transplantation in the canine. In: Shifrine M, Wilson FD (eds) The canine as a biolomedical research model: immunological, hematological, and oncological aspects. Technical Information Service, US Department of Energy, Springfield, VA, pp 153–202
Waldman TH, Goldman CK, Robb RJ et al. (1984) Expression of interleukin 2 receptors on activated human B cells. J Exp Med 160:1450–1466
Wang A, Lu S-D, Mark DF (1984) Site specific mitogenesis of the human interleukin gene structure-function analysis of the cysteine residues. Science 224:1431–1434
Zar JH (1984) In: Zar JH (ed) Biostatistical analysis. Prentice-Hall, Englewood Cliffs, NJ, pp 130–144
Zubler RH, Lowenthal JW, Erard F et al. (1984) Activated B cells expres receptors for and proliferate in response to pure interleukin 2. J Exp Med 160:1170–1183
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cain, G.R., Kawakami, T., Taylor, N. et al. Effects of administration of recombinant human interleukin-2 in dogs. Comparative Haematology International 2, 201–207 (1992). https://doi.org/10.1007/BF00216095
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00216095